Lidocaini Hydrochloridum Noridem

Lidocaine Hydrochloride, the active ingredient in Lidocaini Hydrochloridum Noridem, is a local anesthetic presented as a sterile solution for epidural, intradermal and intramuscular use. It provides reversible nerve block for minor surgical, obstetric and diagnostic procedures in adult patients. GNH USA supplies Lidocaini Hydrochloridum Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine Hydrochloride is employed in the management of pain through local anesthetic action across several clinical settings. - Minor surgical procedures: produces rapid, reversible loss of sensation to facilitate incision and suturing. - Labor analgesia: enables epidural pain control during childbirth, improving maternal comfort. - Diagnostic procedures: provides infiltration anesthesia for biopsies, endoscopies and other minor interventions.

Adverse reactions may occur following administration of lidocaine hydrochloride.

Common Side Effects: - Transient burning or stinging at the injection site. - Mild erythema or swelling around the administration area. - Dizziness or light‑headedness.

Serious or Rare Side Effects: - Systemic toxicity manifesting as seizures or central nervous system depression. - Cardiac arrhythmias, including ventricular tachycardia. - Methemoglobinemia, a rare disorder affecting oxygen transport.

Prior to using lidocaine hydrochloride, clinicians should consider several safety measures. - Assess allergy: confirm no known hypersensitivity to amide‑type local anesthetics. - Monitor cardiovascular status: observe for signs of toxicity during high‑dose administration. - Use caution in patients with hepatic impairment: consider dose adjustment. - Avoid concurrent use with other sodium channel blockers: increased risk of cardiotoxicity. - Store at room temperature: keep in original container, protect from light and moisture.

Lidocaine hydrochloride can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): may potentiate cardiotoxicity. - Beta‑blockers (e.g., propranolol): increase risk of severe hypotension. - General anesthetics (e.g., propofol): additive central nervous system depression.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may increase bleeding risk at injection site. - CYP3A4 inhibitors (e.g., erythromycin): may raise plasma lidocaine levels.